Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014066 | 1.00 | ADRB3 (0.77) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL6818335 | 0.99 | ADRB3 (0.77) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL6818329 | 0.99 | ADRB3 (0.77) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6814376 | 0.94 | ADRB3 (0.75) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6814366 | 0.94 | ADRB3 (0.75) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6809894 | 0.94 | ADRB3 (0.73) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6809890 | 0.94 | ADRB3 (0.73) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6812797 | 0.92 | ADRB3 (0.70) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6812813 | 0.92 | ADRB3 (0.70) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6814868 | 0.92 | ADRB3 (0.73) | ADRB3ADRB2LMNAHIF1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6538152-B1 | Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | claimed |
| EP-1095932-A1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-05-02 | — | — | EP | claimed |
| US-20100197788-A9 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20080306160-A1 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1938837-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY DECREASE IN LACRIMAL FLUID | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| EP-1095932-B1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6538152-B1 | Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
| EP-1095932-A1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.